ARID5A is a dual-function nucleic acid-binding protein that regulates gene expression through both transcriptional and post-transcriptional mechanisms. As a transcription factor, it binds AT-rich DNA sequences and can act as a corepressor of estrogen receptor-mediated transcription 1. As an RNA-binding protein, ARID5A stabilizes inflammatory mRNAs by binding conserved stem-loop structures in their 3′ UTRs, including IL6, STAT3, TBX21, and TNFRSF4 (OX40), competing with mRNA-destabilizing proteins to prevent degradation. Upon inflammatory stimulation, ARID5A translocates to the cytoplasm where it stabilizes IL-17 target mRNAs and regulates ribosomal RNA interactions critical for protein synthesis 2. ARID5A dysregulation contributes to multiple autoimmune and inflammatory diseases; knockout mice are refractory to autoantibody-induced glomerulonephritis and experimental autoimmune encephalomyelitis, while its inhibition prevents septic shock 34. In glioma, high ARID5A expression correlates with poor prognosis and increased tumor-infiltrating immune cells 5. Recent evidence also implicates ARID5A in cardiac aging through MAVS mRNA stabilization-driven inflammation 6, and in metabolic regulation where it represses lipid uptake genes in muscle to enhance insulin sensitivity 7. Targeting ARID5A represents a potential therapeutic strategy for inflammatory diseases and cancer.